Is There a Shortage of Mounjaro, and What Does It Mean for You?

Why there is a shortage of Mounjaro in the UK

The shortage of tirzepatide in the UK is primarily a demand problem, not a manufacturing one. NICE published its recommendation for Mounjaro in December 2024, opening the door to NHS prescribing for eligible patients and signalling to the private market that clinical endorsement had arrived. Prescriptions climbed sharply. Eli Lilly's UK supply, which had been calibrated for a more gradual uptake, could not immediately absorb a near-vertical increase in orders.

Higher doses have been the tightest. Patients who start at 2.5mg and titrate upward every four weeks can reach 7.5mg or 10mg within a few months, so demand at the upper end of the schedule concentrated quickly. The 2.5mg and 5mg starter pens have generally been more available. That said, the picture shifts from week to week, and what was scarce in one month may be back on shelves the next. Current shortage status updates are a more reliable guide than any static snapshot.

The situation is not unique to the UK. Similar shortages affected the United States and parts of Europe as tirzepatide volumes grew. Lilly has expanded manufacturing capacity, but significant increases in output take time to filter through to pharmacy shelves. For now, the shortage of Mounjaro is a structural mismatch between supply and a genuinely enthusiastic clinical response.

What a shortage means if you are already on treatment

If you are mid-treatment and your current dose is unavailable, the decision you face is not straightforward. Stopping abruptly, dropping to a lower dose, or switching to a different medicine are all clinically significant choices. None of them should be made by you alone on the basis of what is in stock, they should be made with your prescriber.

That said, there are practical things worth knowing. Staying at a lower dose temporarily is generally preferable to stopping altogether, and your prescriber can advise whether that is appropriate for you. Switching to another licensed weight-loss treatment is possible in some cases, but again requires clinical assessment. What you should not do is source Mounjaro from an unverified seller because your usual pharmacy is out of stock. The MHRA has warned repeatedly about counterfeit pens circulating in the UK, and supply pressure creates exactly the conditions in which unsafe sources exploit worried patients.

At nume, our prescribers check stock before your order is confirmed. If a dose is unavailable, you will be told, not left waiting or quietly switched without explanation. Our pharmacy holds relationships within the licensed UK supply chain, and we update availability in real time.

How to decide whether to wait or explore alternatives

The Mounjaro shortage in the UK does not affect everyone equally. Your decision depends on which dose you are taking, how long you have been on treatment, and what alternatives your prescriber considers clinically appropriate. A few practical factors are worth weighing.

First, confirm whether the shortage applies to your dose specifically. Dose-level shortage information can help you check this before assuming you are affected. Second, if you are newly starting treatment, the 2.5mg pen has been more consistently available, delays, where they occur, tend to affect higher doses. Third, consider whether the timing matters to you clinically. For some people, a short gap of one or two weeks is manageable; for others, treatment continuity is a priority and switching may make more sense.

On the cost side, shortage conditions have contributed to price volatility. If you are comparing providers during a shortage, the Mounjaro price comparison page sets out what market pricing currently looks like and what a legitimate price actually includes, prescription, clinical oversight, aftercare. A price that looks unusually low during a shortage period is a warning sign, not a bargain.

What nume does not do, and why it matters during a shortage

Shortages create pressure to cut corners. Some providers have responded by substituting doses without explicit clinical review, delaying prescriptions while charging for consultations, or offering medicines from supply chains that cannot be verified. None of that happens here. Every prescription at nume is reviewed by a real GPhC-registered prescriber (a person, not an automated filter) and that review happens the same day you submit your consultation.

We do not ship a substitute dose without a prescriber approving the change. We do not hold your consultation fee if we cannot fill your order. And we do not use shortage conditions to create urgency or push you toward a purchase. Mounjaro is a prescription-only medicine; the clinical assessment is the product, and it comes first every time. If you would like to check availability and suitability for your situation, our prescribers are available seven days a week. Order by 12pm on a weekday and, once approved, your treatment ships the same day and arrives with DPD the next working morning.

The Mounjaro overview page covers the medicine's licence, evidence and eligibility criteria in full. For a broader view of how the shortage has developed over time, the tirzepatide shortage background traces the supply picture from the initial rollout. If you have questions before starting a consultation, our team is reachable via the contact page. Start your free consultation when you are ready and our prescribers will confirm exactly what is available for you.